Catalyst Pharmaceuticals — Key Risks
Small Patient Populations Force High Prices and Perfect Market Penetration
The diseases treated by FIRDAPSE® (a rare neuromuscular condition) and AGAMREE® (Duchenne muscular dystrophy) affect very few people. This forces the company to charge high per-patient prices and capture a large share of a tiny market just to be profitable. Critically, patients who stop treatment are nearly impossible to replace given the limited pool available.
Orphan Drug Exclusivity Is the Main Competitive Moat — and It Could Crack
Because patent protection for some products is limited, the company relies heavily on orphan drug exclusivity (a government-granted period, up to 7 years, blocking competitors from selling the same drug for the same condition). This exclusivity can be lost if a competitor's drug is deemed clinically superior, if supply runs short, or if Congress changes the Orphan Drug Act. An active Paragraph IV patent challenge from a generic manufacturer (Hetero) targeting FIRDAPSE® is already in litigation.
FYCOMPA® Carries a Black Box Warning That May Deter Prescribers
FYCOMPA®, the epilepsy drug acquired from Eisai in January 2023, carries the FDA's most serious label warning (boxed warning) for psychiatric and behavioral side effects — including aggression, hallucinations, and homicidal ideation. These events occurred even in patients with no prior psychiatric history. This stigma may make both patients and doctors reluctant to start or continue treatment, directly capping the drug's revenue potential.
Drug Pricing Pressure From Government Programs Is Intensifying
Multiple overlapping federal initiatives — the Inflation Reduction Act price negotiation program, the "Most Favored Nation" executive order, and new CMS models (GLOBE and GUARD) — all push toward tying U.S. drug prices to lower international benchmarks. If these apply to the company's products, net revenue per prescription could fall materially. Orphan-only drugs currently have some protection from IRA negotiations, but that protection has conditions attached.
Supply Dependence on Outside Partners Creates Fragility
The company has no manufacturing facilities of its own. It must purchase AGAMREE® active ingredients from Santhera and FYCOMPA® supplies from Eisai through at least the end of 2029 — both sourcing from outside the U.S. If either partner faces disruptions, raises prices, or fails financially, the company has limited ability to quickly find alternatives. A U.S. backup supplier for AGAMREE® is not expected to be in place until end of 2026.
Pharmaceutical Import Tariffs Could Raise Costs Across the Product Line
The U.S. Commerce Department launched a national security investigation into pharmaceutical imports in April 2025, and the Trump administration announced plans for up to 100% tariffs on imported branded drugs. Since the company sources active pharmaceutical ingredients (API) and finished products from foreign suppliers, tariffs could raise costs significantly. Royalties owed under licensing deals may also be subject to tariffs.
FDA Disruptions and Staff Reductions Could Delay Regulatory Progress
Federal workforce reductions in 2025 have reduced staffing at the FDA, and a 43-day government shutdown halted non-essential FDA activities. For a company that depends on regulatory approvals to expand into new indications and markets — including Japan and Canada for FIRDAPSE® — any slowdown in FDA responsiveness directly delays revenue-generating opportunities.